Featured in NEJM Journal Watch: A New Medicine for Psoriatic Arthritis? — Physician’s First Watch
Featured in NEJM Journal Watch: A New Medicine for Psoriatic Arthritis?
By the NEJM Journal Watch Editors
Brodalumab, an investigational anti-IL17 receptor A monoclonal antibody, significantly improved psoriatic arthritis at week 12 compared with placebo, as measured by the primary end point — 20% improvement in the American College of Rheumatology response criteria. The findings appear in the New England Journal of Medicine.